A broad scope of Imperacer case studies and peer-reviewed publications are available upon request.
|Phase-I “Proof of Principle”: Immunization with Virosome-Gp41-Derived Antigen Induces Mucosal Antibodies with Antiviral Properties to Reduce Risk of HIV-1 Infection||request reprint|
|Development and GLP-Validation of Imperacer® (Immuno-PCR) Methods for Ultra sensitive Quantification of Mucosal Antibodies in Support of Phase-I Clinical Trial for a Novel Vaccination Strategy in Preventing HIV Infection||request reprint|
|Randomized Phase I: Safety, Immunogenicity and Mucosal Antiviral Activity in Young Healthy Women Vaccinated with HIV-1 Gp41 P1 Peptide on Virosomes||request reprint|
|Ultra Sensitive Cytokine Quantification||request reprint|
|Imperacer® (Immuno-PCR) Method Development and Validation for Ultra Sensitive Quantification of Interferon Gamma in Human Plasma to Support Clinical Phase I of a Cancer Vaccine Candidate||request reprint|
|Highly Sensitive Cytokine Quantification using Imperacer®, an Immuno-PCR based Ligand-Binding Assay System||request reprint|
|Development and Validation of an Ultra Sensitive Imperacer (Immuno-PCR) Method for Quantification of Human Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)||request reprint|
|Challenges in Developing a Sensitive PD Assay–From Tool Selection to Technology Evaluation||request reprint|
|An Ultrasensitive Immuno-qPCR Assay for Quantitation of Intact Pegylated Interferon Beta-1a in Human Serum||request reprint|
|Clinical Biomarker Quantification: Novel Tools for Pharmacodynamic Applications||request reprint|
|Challenges in Developing a Sensitive PD Assay–From Tool Selection to Technologies Evaluation||request reprint|
Please feel free to contact Chimera Biotec’s team of dedicated scientists for more in-depth information. We are looking forward to provide you with the immunoassay to exceed your highest expectations.